Antonia S, et al. Overall survival with durvalumab versus placebo after chemoradiotherapy in stage III NSCLC: updated results from PACIFIC. IASLC 2018, abstract PL02.01.
MRI-gestuurde radiotherapie en restaging bij slokdarmkanker
feb 2021 | Maag-darm-leveroncologie, Radiotherapie